BioCryst Pharmaceuticals (BCRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BCRX BioCryst Pharmaceuticals

Watchlist

7.350
-1.080-12.81%

Close Nov 4 16:00 ET

7.160
-0.190-2.59%

Post 16:52 ET

1.52BMarket Cap-12049P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $14
Moomoo News14:31 ET · Ratings
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga11:40 ET
TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20
Moomoo News11:31 ET · Ratings
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript Summary
moomoo AI11:06 ET · Conference Call
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
Yahoo FinanceNov 4 08:10 ET
Express News | BioCryst Pharmaceuticals Shares Down 5.1% Premarket After Q3 Results
ReutersNov 4 07:23 ET

Comments

frogoracletrading

10 hours ago

$BCRX Support / Resistance Levels

Here are the levels to watch this week.
Larger Image: tradingview.com...
$BioCryst Pharmaceuticals (BCRX.US)$

Trytosaveabit

Oct 14 06:13

Update

$BioCryst Pharmaceuticals (BCRX.US)$ BioCryst's ORLADEYO Reduces Hospital Visits and Emergency Care for Hereditary Angioedema Patients, Study Shows
Benzinga· 3 mins ago
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reduc...

Trytosaveabit

Sep 30 06:02

News

$BioCryst Pharmaceuticals (BCRX.US)$ Reuters
Just
U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile

Analysts Notebook

Sep 5 06:06

Columns 'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio

The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...